- Home
- MTNB vs MBIO Comparison
MTNB vs MBIO Comparison
Compare MTNB & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | MBIO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 4.2M |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MTNB | MBIO |
|---|---|---|
| Price | $0.18 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 921.9K | 20.8K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 59.84 | ★ 98.99 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,750.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $0.52 |
| 52 Week High | $2.14 | $1.84 |
Technical Indicators
Market Signals| Indicator | MTNB | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 45.15 |
| Support Level | $0.18 | $0.53 |
| Resistance Level | $0.27 | $0.66 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 8.53 | 43.82 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.